Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2010 Aug;32(8):1040-7.
doi: 10.1002/hed.21285.

Chemotherapy alone for organ preservation in advanced laryngeal cancer

Vasu Divi  1 , Francis P Worden, Mark E Prince, Avraham Eisbruch, Julia S Lee, Carol R Bradford, Douglas B Chepeha, Theodoros N Teknos, Norman D Hogikyan, Jeffrey S Moyer, Christina I Tsien, Susan G Urba, Gregory T Wolf
Affiliations
Clinical Trial

Chemotherapy alone for organ preservation in advanced laryngeal cancer

Vasu Divi et al. Head Neck. 2010 Aug.

Abstract

Background: For patients with advanced laryngeal cancer, a trial was designed to determine if chemotherapy alone, in patients achieving a complete histologic complete response after a single neoadjuvant cycle, was an effective treatment with less morbidity than concurrent chemoradiotherapy.

Methods: Thirty-two patients with advanced laryngeal or hypopharyngeal cancer received 1 cycle of induction chemotherapy, and subsequent treatment was decided based on response.

Results: A histologic complete response was achieved in 4 patients and were treated with chemotherapy alone. All 4 patients' cancer relapsed in the neck and required surgery and postoperative radiotherapy (RT). Twenty-five patients were treated with concomitant chemoradiation. Three patients were treated with surgery. Overall survival and disease-specific survival at 3 years were 68% and 78%, respectively.

Conclusion: Chemotherapy alone is not feasible for long-term control of regional disease in patients with advanced laryngeal cancer even when they achieve a histologic complete response at the primary site.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Study Design
Figure 2a
Figure 2a
Overall Survival Estimate
Figure 2b
Figure 2b
Disease Specific Survival Estimate
Figure 2c
Figure 2c
Time to recurrence or secondary primary
Figure 2d
Figure 2d
Local control estimate
See this image and copyright information in PMC

References

    1. Wolf GT. The VA Laryngeal Cancer Study Group. Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. New Engl J of Med. 1991;324:1685–1690. - PubMed
    1. Urba SG, Wolf GT, Eisbruch A, et al. Single-Cycle Induction Chemotherapy Selects Patients With Advanced Laryngeal Cancer for Combined Chemoradiation: A New Treatment Paradigm. J Clin Oncol. 2006;24:593–8. - PubMed
    1. Bentzen SM, et al. Increasing toxicity in nonoperative head and neck cancer treatment: Investigations and interventions. Int J. Radiation Oncology Biol. Phys. 2007;69:S79–S82. - PubMed
    1. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92(3):205–16. - PubMed
    1. Laccourreye O, Brasnu D, Bassot V, et al. Cisplatin-Fluorouracil Exclusive Chemotherapy for T1-T3NO Glottic Squamous Cell Carcinoma Complete Clinical Responders: Five-Year Results. J Clin Oncol. 1996;14:2331–6. - PubMed

Publication types

MeSH terms